Administration of Tumor Cell Chromatin to Immunosuppressed and Non-immunosuppressed Non-human Primates

For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residu...

Full description

Saved in:
Bibliographic Details
Published inBiologicals Vol. 23; no. 3; pp. 221 - 224
Main Authors Wierenga, D.E., Cogan, J., Petricciani, J.C.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.09.1995
Subjects
Online AccessGet full text

Cover

Loading…
Abstract For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residual impurity by injecting both normal and immunosuppressed monkeys with 10 8genome equivalents of DNA from a human tumor cell line. After more than eight years of observation, none of the animals shows evidence of neoplastic disease. The results of this study along with clinical experiences with already approved products derived from continuous cell lines suggest that he benefits of using such cells for the production of biologicals far outweigh any theoretical risks associated with DNA.
AbstractList For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residual impurity by injecting both normal and immunosuppressed monkeys with 10 super(8) genome equivalents of DNA from a human tumor cell line. After more than eight years of observation, none of the animals shows evidence of neoplastic disease. The results of this study along with clinical experiences with already approved products derived from continuous cell lines suggest that he benefits of using such cells for the production of biologicals far outweigh any theoretical risks associated with DNA. (DBO)
For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residual impurity by injecting both normal and immunosuppressed monkeys with 10 8genome equivalents of DNA from a human tumor cell line. After more than eight years of observation, none of the animals shows evidence of neoplastic disease. The results of this study along with clinical experiences with already approved products derived from continuous cell lines suggest that he benefits of using such cells for the production of biologicals far outweigh any theoretical risks associated with DNA.
For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residual impurity by injecting both normal and immunosuppressed monkeys with 10(8) genome equivalents of DNA from a human tumor cell line. After more than eight years of observation, none of the animals shows evidence of neoplastic disease. The results of this study along with clinical experiences with already approved products derived from continuous cell lines suggest that he benefits of using such cells for the production of biologicals far outweigh any theoretical risks associated with DNA.
Author Wierenga, D.E.
Cogan, J.
Petricciani, J.C.
Author_xml – sequence: 1
  givenname: D.E.
  surname: Wierenga
  fullname: Wierenga, D.E.
  organization: Pharmaceutical Research and Manufacturers of America, Washington, DC, U.S.A
– sequence: 2
  givenname: J.
  surname: Cogan
  fullname: Cogan, J.
  organization: Food and Drug Administration, Bethesda, MD, U.S.A
– sequence: 3
  givenname: J.C.
  surname: Petricciani
  fullname: Petricciani, J.C.
  organization: Genetics Institute, Cambridge, MA, U.S.A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/8527121$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1LxDAQxYOs6Ppx9Sbk5K3rJGmS9iiLHwuLetBzSJsEI9tkTVrB_96WXTwI4mmGeb95MPNO0CzEYBG6ILAgAOK68XGzIHXNFwBMHKA5gZoXFaMwm_qSFwS4OEYnOb8DEFLK8ggdVZxKQskcuRvT-eBzn3TvY8DR4Zehiwkv7WaDl28pdqMQcB_xquuGEPOw3SabszVYB4MfYyj8b2Eavg2dDvg5-XHf5jN06PQm2_N9PUWvd7cvy4di_XS_Wt6si5ZWvC-M4y2nVSlZKYyTjZa1ZAKsdJwxJrQhVEvtBNTMTUQrgAJjnDZgZONqdoqudr7bFD8Gm3vV-dyOp-hg45CVlJKRGqp_QcIrKaCiI7jYgW2KOSfr1Ha6KX0pAmpKQE0JqCkBNSUwLlzunYems-YH37981Kudbsc_fHqbVG69Da01Ptm2Vyb6v6y_AZhsl-w
CitedBy_id crossref_primary_10_1002_btpr_1548
crossref_primary_10_1089_hum_2005_16_393
crossref_primary_10_3389_fmicb_2020_00372
crossref_primary_10_1016_j_jchromb_2006_11_018
crossref_primary_10_1016_j_yrtph_2007_10_011
crossref_primary_10_1089_aid_1998_14_627
crossref_primary_10_1007_BF02841511
crossref_primary_10_3390_microorganisms1010100
crossref_primary_10_1016_j_memsci_2018_10_058
crossref_primary_10_1586_14760584_6_4_547
ContentType Journal Article
Copyright 1995
Copyright_xml – notice: 1995
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
8FD
FR3
P64
7X8
DOI 10.1006/biol.1995.0036
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Engineering Research Database

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1095-8320
EndPage 224
ExternalDocumentID 10_1006_biol_1995_0036
8527121
S104510568570036X
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
23N
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
9JM
AAAJQ
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXUO
ABBQC
ABFNM
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEJ
HMG
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
LCYCR
LG5
LUGTX
LZ5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSH
SSI
SSU
SSZ
T5K
UNMZH
WUQ
XPP
ZMT
~G-
~KM
AAHBH
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
8FD
FR3
P64
7X8
ID FETCH-LOGICAL-c285t-df5c52847346df7ba797360e7f53336ad12a7af6093f46dfc60203352b0d7bf93
IEDL.DBID AIKHN
ISSN 1045-1056
IngestDate Fri Aug 16 23:17:55 EDT 2024
Sat Aug 17 00:28:05 EDT 2024
Thu Sep 26 18:25:03 EDT 2024
Sat Sep 28 07:38:20 EDT 2024
Fri Feb 23 02:34:22 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c285t-df5c52847346df7ba797360e7f53336ad12a7af6093f46dfc60203352b0d7bf93
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 8527121
PQID 15876082
PQPubID 23462
PageCount 4
ParticipantIDs proquest_miscellaneous_77731908
proquest_miscellaneous_15876082
crossref_primary_10_1006_biol_1995_0036
pubmed_primary_8527121
elsevier_sciencedirect_doi_10_1006_biol_1995_0036
PublicationCentury 1900
PublicationDate 1995-Sep
PublicationDateYYYYMMDD 1995-09-01
PublicationDate_xml – month: 09
  year: 1995
  text: 1995-Sep
PublicationDecade 1990
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biologicals
PublicationTitleAlternate Biologicals
PublicationYear 1995
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0011474
Score 1.5103027
Snippet For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 221
SubjectTerms Animals
Chromatin - immunology
DNA, Neoplasm - administration & dosage
DNA, Neoplasm - adverse effects
DNA, Neoplasm - immunology
Humans
Immunocompromised Host
Macaca mulatta
Neoplasms - etiology
Primates
Tumor Cells, Cultured
Title Administration of Tumor Cell Chromatin to Immunosuppressed and Non-immunosuppressed Non-human Primates
URI https://dx.doi.org/10.1006/biol.1995.0036
https://www.ncbi.nlm.nih.gov/pubmed/8527121
https://search.proquest.com/docview/15876082
https://search.proquest.com/docview/77731908
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1NaxsxEIaH2CbQS0mamLpNHR0CPanetb52j8E02EljQpuAb4u0ksDg7BrHPuSS317NfgQS6kuvuxIMM9qZl5XmEcCFisexzRNDvfOMcmY4TYVNaMJZkitjIltxtm_ncvrArxdicQCTthcGj1U2ub_O6VW2bp6MGm-O1svl6E-MaJRQvytEO5OLDvRCOeK8C73L2c10_rqZEPMKxozjKU5o2Y2RHCHpCBv28MdKRWn-Z23apz2rGnR1BB8b8Ugua_uO4cAVn-Cwvk7y-QT8WxIuKT253z2WGzJxqxVBDC7K04JsSzLDtpDyabeuzsE6S3Rhybws6PL9C3xYXeRH7hBMEZTpKTxc_byfTGlzjwLNx4nYUutFLrAMMS6tV0arVDEZOeWD1mNS23islfYySpnHEbnE7cmgzEKklPEp60O3KAv3GYhJfSS1S7lGEJ3nOiiIPBKGG2lVIvQAvrcezNY1LiOrwcgyQ19n6GvkkcoBxK2DszcBz0Iu3zvnvI1EFr4C3NrQhSt3T1ksQlYPtuwfoZQK2SZKBtCvQ_hqXyLGuGK__IdBX-FD3eKOZ87OoLvd7Ny3IFK2ZgidHy_xMCzFye9fd8NmSf4FrAro5A
link.rule.ids 315,786,790,4521,24144,27957,27958,45620,45714
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fSyMxEB56Hsfdi-ipXPXUPBz4FLvbbJLdx6MorT_KgRX6FpJNAgXdLdo-3Mv97Wayu4JyffE1mYVhJjvzkcx8A_BLpsPUlrmh3nlGM2YyWnCb0zxjeSmNSWzk2b6divF9djXn8x6Mul4YLKtsY38T02O0blcGrTUHy8VicJciNUrI35GinYn5J_iMcB7nN5z_e63zCHg_UjGjNEXxjrkxEQPkOcJ2PbxWiRzN_81Mm5BnzECXO7DdQkfyu9FuF3qu-g5fmmGSf_fAv-XBJbUns_Vj_URG7uGBIAkugtOKrGoywaaQ-nm9jFWwzhJdWTKtK7p4v4GLcYwf-YO0FAGX7sP95cVsNKbtFAVaDnO-otbzkmMSYpmwXhotC8lE4qQPSI8JbdOhltqLpGAeJUqBj5MBlwU_SeMLdgBbVV25H0BM4ROhXZFppKHzmQ74oUy4yYywMue6D2edBdWyIctQDS2yUGhrhbZGNlLRh7QzsHrjbhUi-cZvTjtPqPAP4MOGrly9flYpDzE96LJZQkoZYk2S9-GgceGrfjkf4nk9_IBCp_B1PLu9UTeT6fURfGua3bH67CdsrZ7W7jjAlZU5icfxBWcq6B0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Administration+of+tumor+cell+chromatin+to+immunosuppressed+and+non-immunosuppressed+non-human+primates&rft.jtitle=Biologicals&rft.au=Wierenga%2C+D+E&rft.au=Cogan%2C+J&rft.au=Petricciani%2C+J+C&rft.date=1995-09-01&rft.issn=1045-1056&rft.volume=23&rft.issue=3&rft.spage=221&rft_id=info:doi/10.1006%2Fbiol.1995.0036&rft_id=info%3Apmid%2F8527121&rft.externalDocID=8527121
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1045-1056&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1045-1056&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1045-1056&client=summon